DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

May 30, 2024

GBM: Significant Survival Data Announced

New Announcement from Ivy Brain Tumor Center

The Ivy Brain Tumor Center at Barrow Neurological Institute announced a clinical readout of a Phase 0/2 ‘trigger’ clinical trial of niraparib in patients with newly diagnosed MGMT-unmethylated Glioblastoma. The study concluded that niraparib achieved pharmacologically relevant concentrations, in excess of any other PARP inhibitor in Glioblastoma tumor tissue and led to a median overall survival of 20.3 months, a significant advance beyond the historical control of 12.7 months.

Ivy brain tumor center

The drug, niraparib is an oral, once-daily PARP inhibitor with current indications in first-line maintenance for advanced ovarian cancer.

Click the button below to download the End Brain Cancer Initiative's disease education Mobile Application to learn more about niraparib, as well as other new research and clinical trials in the brain cancer space.

These results will be presented in an oral presentation on June 3, 2024, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.


Sponsor logos

Hand holding cell phone displaying app

EBCI App QR

Scan or click the QR code to download the App now!

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram